Co-receptor antagonists as HIV-1 entry inhibitors

Current Opinion in Infectious Diseases

Volumn 17, Issue 1, 2004, Pages 7-16

  Shaheen, Farida ^a   Collman, Ronald G ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b 522 Johnson Pavilion ^*  (United States)

Author keywords

CCR5; Chemokine receptor; CXCR4; G protein coupled receptor; gp120; Viral entry; Viral envelope

Indexed keywords

1 ACETYL N [3 [4 (4 CARBAMOYLBENZYL) 1 PIPERIDINYL]PROPYL] N (3 CHLORO 4 METHYLPHENYL) 4 PIPERIDINECARBOXAMIDE; 1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; AMD 070; APLAVIROC; CD4 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; E 913; INHIBITOR PROTEIN; KRH 1636; MARAVIROC; MONOCLONAL ANTIBODY; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PRO 140; RECEPTOR BLOCKING AGENT; SMALL MOLECULE ANTAGONIST; T 140; T 22; UNCLASSIFIED DRUG; VICRIVIROC; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIBIOTIC RESISTANCE; DRUG EFFECT; DRUG SELECTIVITY; ENVELOPE GENE; EVOLUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHENOTYPE; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; VIRUS INHIBITION; DRUG ANTAGONISM;

ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HUMANS; RECEPTORS, CCR5; RECEPTORS, CXCR4;

EID: 3042780489     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200402000-00003     Document Type: Review

References (67)

1. Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999; 282:1627-1632.
2. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348:2186-2195. This study describes the results from the first large clinical study using an HIV-1 entry inhibitor, enfurvitide, which acts at a stage of entry subsequent to chemokine receptor binding that is reviewed here.
3. Pierson TC, Doms RW. HIV-1 entry inhibitors: new targets, novel therapies. Immunol Lett 2003; 85:113-118.
4. Kazmierski W, Bifulco N, Yang H, et al. Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorg Med Chem 2003; 11:2663-2676. This is an excellent review of small-molecule CCR5 antagonists, with an emphasis on the biochemistry of these agents.
5. Kilby JM, Eron JJ. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med 2003; 348:2228-2238. This is an excellent review of new antiviral agents designed to interfere with all stages of entry, with an emphasis on clinical applicability and patient-related issues.
6. Starr-Spires LD, Collman RG. HIV-1 entry and entry inhibitors as therapeutic agents. Clin Lab Med 2002; 22:681-701.
7. Resch W, Hoffman N, Swanstrom R. Improved success of phenotype prediction of the human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural networks. Virology 2001; 288:51-62.
8. Daar ES, Ling Li X, Moudgil T, Ho DD. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A 1990; 87:6574-6578.
9. Jacobson JM, Lowy I, Fletcher CV, et al. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J Infect Dis 2000; 182:326-329.
10. Yang AG, Bai XF, Huang XF, et al. Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection. Proc Natl Acad Sci U S A 1997; 94:11567-11572.
11. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection of Caucasian individuals bearing mutant alleles of the CCR5 chemokine receptor gene. Nature 1996; 382:722-725.
12. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CCR5 structural gene. Science 1996; 273:1856-1862.
13. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18:217-243.
14. Cocchi F, DeVico AL, Garzino-Demo A, et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270:1811-1815.
15. Pastore C, Picchio GR, Galimi F, et al. Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES. Antimicrob Agents Chemother 2003; 47:509-517. This study shows that co-receptor function may be inhibited both by steric blocking of gp120 binding and by inducing the internalization of the receptor with prolonged sequestration before re-expression.
16. Paliard X, Lee AY, Fraud N, et al. Performance-enhanced synthetic nonakine is a highly potent inhibtor of HIV-1 infection. In: The 2nd IAS Conference on HIV Pathogenesis and Treatment. Abstract No. 536, Paris, France. July 13-16, 2003.
17. Gaertner H, Cerini F, Kunzi G, et al. PSC-RANTES: development and characterization of a potent HIV-1 entry inhibitor. In: The 2nd IAS Conference on HIV Pathogenesis and Treatment. Abstract No. 537. Paris, France, July 13-16, 2003.
18. Trkola A, Ketas TJ, Nagashima KA, et al. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol 2001; 75:579-588.
19. Olson WC, Gardner JP, Ketas TJ, et al. Inhibition of HIV-1 entry without coreceptor antagonism by the humanized anti-CCR5 antibody PRO 140. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Abstract No. H178, San Diego, CA. 2002. This study shows that it might be possible to separate-the blocking of HIV-1 entry and the blocking chemokine-elicited signaling through a receptor. This issue might be very important if the inhibition of normal receptor function leads to serious deleterious consequences for inflammation or immunity.
20. Franti M, Nagashima K, Maddon P, et al. The CCR5 co-receptor inhibitor PRO 140 effectively controls established HIV-1 infection in vivo. In: 9th Conference on Retroviruses and Opportunistic Infections. Abstract No. 403-T, Seattle, WA. February 24-28, 2002.
21. Cormier EG, Ketas TJ, Sullivan BM, et al. Baseline viral susceptibility to the CCR5 co-receptor inhibitor PRO 140. In: The 2nd IAS Conference on HIV Pathogenesis and Treatment. Abstract No. 530, Paris, France, July 13-16, 2003.
22. Baba M, Nishimura O, Kanzaki N, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A 1999; 96:5698-5703.
23. Takashima K, Miyake H, Furuta RA, et al. Inhibitory effects of small-molecule CCR5 antagonists on human immunodeficiency virus type 1 envelope-mediated membrane fusion and viral replication. Antimicrob Agents Chemother 2001; 45:3538-3543.
24. Dragic T, Trkola A, Thompson DA, et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci U S A 2000; 97:5639-5644.
25. Tremblay CL, Giguel F, Hicks JL, et al. TAK-220, A novel small molecule inhibitor of CCR5 has favorable anti-HIV interactions with other antiretrovirals in vitro. In: 10th Conference on Retroviruses and Opportunistic Infections. Abstract No.562. Boston, MA, February 10-14, 2003.
26. Lizawa Y, Kanzaki N, Takashima K, et al. Anti-HIV-1 activity of TAK-220, a small molecule CCR5 antagonsit. In: 10th Conference on Retroviruses and Opportunistic Infections. Oral Session 4, Abstract No.11. Boston, MA. February 10-14, 2003.
27. Tagat JR, Steensma RW, McCombie SW, et al. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)- carbonyl]-4-methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl] -1-piperazi nyl]-piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist. J Med Chem 2001; 44:3343-3346.
28. Tsamis F, Gavrilov S, Kajumo F, et al. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol 2003; 77:5201-5208. This study shows that anti-HIV chemokine receptor antagonists may act both by steric blocking of gp120 binding and by affecting the overall conformation of the molecule so that gp120 can no longer bind.
29. Reynes J, Rouzier R, Kanouni T, et al. SCH C: Safety and antiviral effects of a CCR5 receptor antagonist in HIV-1-infected subjects. In: 9th Conference on Retroviruses and Opportunistic Infections. Oral Session 4, Abstract No. 1, Seattle, WA. February 24-28, 2002. This report of short-term monotherapy with a CCR5 blocker demonstrated a 0.5 log or greater reduction in viral load in 10 out of 12 subjects, and offers encouraging proof-of-principle preliminary evidence in favor of CCR5 blocking strategies.
30. Dorr P, Macartney M, Rickett G, et al. UK-427,857, a novel small molecule HIV entry inhibitor is specific antagonist of the chemokine receptor CCR5. In: 10th Conference on Retroviruses and Opportunistic Infections. Oral Session 4, Abstract No. 12, Boston, MA. February 10-14, 2003.
31. Napier C, Dorr P, Gladue R, et al. The preclinical pharmacokinetics and safety pharmacology of the anti-HIV CCR5 antagonist, UK-427, 857. In: 10th Conference on Retroviruses and Opportunistic Infections. Abstract No.546a. Boston, MA. February 10-14, 2003.
32. Abel S, Van der Ryst E, Muirhead GJ, et al. Pharmacokinetics of single and multiple oral doses of UK-427,857 - a novel CCR5 antagonist in healthy volunteers. In: 10th Conference on Retroviruses and Opportunistic Infections. Abstract No.547. Boston, MA. February 10-14, 2003.
33. Maeda K, Yoshimura K, Shibayama S, et al. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J Biol Chem 2001; 276:35194-35200.
34. Maeda K, Nakata H, Miyakawa T, et al. CCR5 binding profiles of AK602/ONO-4128, a novel HIV specific and potent anti-HIV spirodiketopiperazine (SDP) derivative, differ from those other existing CCR5 inhibitors. In: The 2nd IAS Conference on HIV Pathogenesis and Treatment. Abstract No. 531. Paris, France. July 13-16, 2003.
35. Lynch CL, Hale JJ, Budhu RJ, et al. CCR5 antagonists: 3-(pyrrolidin-1-yl)propionic acid analogues with potent anti-HIV activity. Org Lett 2003; 5:2473-2475.
36. Yang YF, Mukai T, Gao P, et al. A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anticollagen T cell responses. Eur J Immunol 2002; 32:2124-2132. Despite the fact that CCR5 is dispensable in individuals homozygous for the defective CCR5Δ32 allele, this study begins to define what role CCR5 plays in inflammation. It also suggests that in addition to their anti-HIV-1 use, CCR5 antagonists might have utility in inflammatory diseases.
37. Zou YR, Kottmann AH, Kuroda M, et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998; 393:595-599.
38. Tachibana K, Hirota S, Iizasa H, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998; 393:591-594.
39. Campbell DJ, Kim CH, Butcher EC. Chemokines in the systemic organization of immunity. Immunol Rev 2003; 195:58-71. This review provides a comprehensive overview of the complex and often redundant chemokine-chemokine receptor networks, and current knowledge of how these pathways participate in inflammation and immunity.
40. Schols D, Struyf S, Van Damme J, et al. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997; 186:1383-1388.
41. Zhang WB, Navenot JM, Haribabu B, et al. A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem 2002; 277:24515-24521. This study shows that agents that interfere with the HIV-1 co-receptor function of the chemokine receptor may differ in the extent to which they block normal receptor function. These differences may be quite important if blocking receptor-mediated signaling in response to chemokines has deleterious effects.
42. Schols D, Claes S, De Clercq E, et al. AMD-3100, a CXCR4 antagonist, reduced HIV viral load and X4 viral levels in humans. In: 9th Conference on Retroviruses and Opportunistic Infections. Oral Session 4, Abstract No. 2. Seattle, WA. February 24-28, 2002. This is the first study of antiviral activity of a small molecule CXCR4 antagonist in infected people. The results highlight the great importance of baseline virus coreceptor phenotype, and suggest that dual chemokine receptor targeting may be necessary in individuals infected with X4 strains.
43. Schols D, Claes S, Hatse S, et al. Anti-HIV activity profile of AMD070, an orally bioavailable CXCR4 antagonist H. In: 10th Conference on Retroviruses and Opportunistic Infections. Abstract No.563, Boston, MA. February 10-14, 2003.
44. Ichiyama K, Yokoyama-Kumakura S, Tanaka Y, et al. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A 2003; 100:4185-4190.
45. Murakami T, Nakajima T, Koyanagi N, et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 1997; 186:1389-1393.
46. Fujii N, Nakashima H, Tamamura H. The therapeutic potential of CXCR4 antagonists in the treatment of HIV. Exp Opin Invest Drugs 2003; 12:185-195. This review focuses on CXCR4 antagonists that inhibit HIV-1, with an emphasis on peptide blockers and on the biochemistry of these agents.
47. Kanbara K, Sato S, Tanuma J, et al. Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134. AIDS Res Hum Retroviruses 2001; 17:615-622.
48. Doranz BJ, Grovit-Ferbas K, Sharron MP, et al. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med 1997; 186:1395-1400.
49. Doranz BJ, Filion LG, Diaz-Mitoma F, et al. Safe use of the CXCR4 inhibitor ALX40-4C in humans. AIDS Res Hum Retroviruses 2001; 17:475-486.
50. Boshoff C, Endo Y, Collins PD, et al. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science 1997; 278:290-294.
51. Kledal TN, Rosenkilde MM, Coulin F, et al. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science 1997; 277:1656-1659.
52. Zhou N, Luo Z, Luo J, et al. Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with D-peptides derived from chemokines. J Biol Chem 2002; 277:17476-17485.
53. Singh A, Collman RG. Heterogeneous spectrum of coreceptor usage among variants within a dualtropic human immunodeficiency virus type 1 primary isolate quasispecies. J Virol 2000; 74:10229-10235.
54. Trkola A, Kuhmann SE, Strizki JM, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A 2002; 99:395-400. This study showed that escape from CCR5 blocking involved mutations that enable virus to use CCR5 in the presence of the blocking agent, and not a switch to using CXCR4 as a co-receptor. Although only an in-vitro study, it provides some reassurance regarding the potentially deleterious effect of encouraging the outgrowth of X4 and R5X4 escape variants, which might be more pathogenic in vivo.
55. Mosier DE, Picchio GR, Gulizia RJ, et al. Highly potent RANTES analogues either prevent CCRS-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J Virol 1999; 73:3544-3550.
56. Zhang YJ, Moore JP. Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry? J Virol 1999; 73:3443-3448.
57. Yi YJ, Singh A, Isaacs SN, Collman RG. A CCR5/CXCR4-independent coreceptor pathway on human macrophages supports efficient SIV Env-mediated fusion but not infection: Implications for alternative pathways of viral entry. Virology 2001; 284:142-151.
58. Chen ZW, Kwon D, Jin ZQ, et al. Natural infection of a homozygous Delta24 CCR5 red-capped mangabey with an CCR2b-tropic simian immunodeficiency virus. J Exp Med 1998; 188:2057-2065.
59. Belnoue E, Kayibanda M, Deschemin JC, et al. CCR5 deficiency decreases susceptibility to experimental cerebral malaria. Blood 2003; 101:4253-4259.
60. Glass WG, Lane TE. Functional analysis of the CC chemokine receptor 5 (CCR5) on virus-specific CD8+ T cells following coronavirus infection of the central nervous system. Virology 2003; 312:407-414. This study shows that CCR5 is expressed on other immune cells besides CD4 T cells, and may be important in immune function.
61. Luangsay S, Kasper LH, Rachinel N, et al. CCR5 mediates specific migration of Toxoplasma gondii-primed CD8 lymphocytes to inflammatory intestinal epithelial cells. Gastroenterology 2003; 125:491-500. Although CCR5 is dispensable in normal people, based on individuals homozygous for the defective CCR5Δ32 allele, this study shows that it plays an important role in CD8 cell function and immunity to Toxoplasma gondii, which is an important pathogen in individuals with AIDS.
62. Honczarenko M, Le Y, Glodek AM, et al. CCR5-binding chemokines modulate CXCL12 (SDF-1)-induced responses of progenitor B cells in human bone marrow through heterologous desensitization of the CXCR4 chemokine receptor. Blood 2002; 100:2321-2329. This report indicates a critical role for both CCR5 and CXCR4 in maintaining normal hematopoetic and immune cell development, with implications for the immune and hematological consequences of long-term blocking.
63. Lapidot T, Kollet O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m (null) mice. Leukemia 2002; 16:1992-2003.
64. Libura J, Drukala J, Majka M, et al. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood 2002; 100:2597-2606.
65. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102(8):2728-30. The CXCR4 blocker AMD3100 dramatically increased the level of circulating CD34-positive stem cells in normal volunteers. This result suggests that these agents may be valuable adjunctive agents in stem cell transplation, but raises questions about how they will affect hematopoesis when given chronically to HIV-infected people.
66. Tamamura H, Hori A, Kanzaki N, et al. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett 2003; 550:79-83.
67. De Clercq E. The bicyclam AMD3100 story. Nat Rev Drug Discov 2003; 2:581-587. An excellent review of the bicyclam CXCR4 inhibitors and what roles they might play as drugs for HIV-1 infection, in cancer, and in inflammatory and other diseases.